What does this research mean for the field?

Nanotechnology-based drug delivery systems utilizing targeted and stimuli-responsive nanocarriers overcome the limitations of conventional formulations by improving drug bioavailability, stability, and site-specific accumulation. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review recent technological advancements in nanotechnology-based drug delivery systems designed to overcome the pharmacological limitations of conventional therapeutic formulations.

September 5, 2026European Journal Pharmaceutical and Medical ResearchOpen Access

Recent Advances in Nanotechnology Based Drug Delivery Systems

View Full Paper

Ask AI

Bookmark

Authors

*B*Y. Venkateswara Rao, T. Naga Pallavi, G. Varshitha, A. Keerthi, G. Sofiya, K. Gowri Sankar, P. Srinivasa Babu

Discussion

Member takes

Overview

Review demonstrates enhanced efficacy and targeted payload release using engineered nanocarriers, indicating significant opportunities to overcome traditional drug toxicity.

Key Points

To review recent technological advancements in nanotechnology-based drug delivery systems designed to overcome the pharmacological limitations of conventional therapeutic formulations.
Synthesized current literature detailing nanocarriers sized between 1 nm and 100 nm, including liposomes, micelles, dendrimers, carbon nanotubes, metallic nanoparticles, and quantum dots.
Evaluated passive mechanisms like enhanced permeability and retention (EPR) alongside active ligand-receptor targeting and stimuli-responsive release platforms.
Engineered nanocarriers substantially improve drug solubility, biological stability, and bioavailability compared to traditional formulations.
Targeted delivery approaches using active surface ligands and passive EPR mechanisms enhance localized drug accumulation at disease sites while sparing healthy tissues.
Stimuli-responsive release mechanisms governed by microenvironmental pH, temperature shifts, and enzymatic activity provide precise spatiotemporal control over drug release.

Cite This Study

*Y. Venkateswara Rao, T. Naga Pallavi, G. Varshitha, A. Keerthi, G. Sofiya, K. Gowri Sankar, P. Srinivasa Babu (2026) studied this question.

synapsesocial.com/papers/6a9bd49d6b95aff0620ec608 https://doi.org/10.5281/zenodo.22267573

View Full Paper

Ask AI

Bookmark

September 5, 2026European Journal Pharmaceutical and Medical ResearchOpen Access

Recent Advances in Nanotechnology Based Drug Delivery Systems

View Full Paper

Ask AI

Bookmark

Authors

*B*Y. Venkateswara Rao, T. Naga Pallavi, G. Varshitha, A. Keerthi, G. Sofiya, K. Gowri Sankar, P. Srinivasa Babu

Discussion

Member takes

Overview

Review demonstrates enhanced efficacy and targeted payload release using engineered nanocarriers, indicating significant opportunities to overcome traditional drug toxicity.

Key Points

To review recent technological advancements in nanotechnology-based drug delivery systems designed to overcome the pharmacological limitations of conventional therapeutic formulations.
Synthesized current literature detailing nanocarriers sized between 1 nm and 100 nm, including liposomes, micelles, dendrimers, carbon nanotubes, metallic nanoparticles, and quantum dots.
Evaluated passive mechanisms like enhanced permeability and retention (EPR) alongside active ligand-receptor targeting and stimuli-responsive release platforms.
Engineered nanocarriers substantially improve drug solubility, biological stability, and bioavailability compared to traditional formulations.
Targeted delivery approaches using active surface ligands and passive EPR mechanisms enhance localized drug accumulation at disease sites while sparing healthy tissues.
Stimuli-responsive release mechanisms governed by microenvironmental pH, temperature shifts, and enzymatic activity provide precise spatiotemporal control over drug release.

Cite This Study

*Y. Venkateswara Rao, T. Naga Pallavi, G. Varshitha, A. Keerthi, G. Sofiya, K. Gowri Sankar, P. Srinivasa Babu (2026) studied this question.

synapsesocial.com/papers/6a9bd49d6b95aff0620ec608 https://doi.org/10.5281/zenodo.22267573

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark